Additional Relevant Details “This CHMP recommendation is particularly notable because it is the first time that MRI-detected structural and inflammatory measures of disease severity are cited as support for the proposed RA indication,” said Paul Emery, M.A., M.D., F.R.C.P., F.Med.Sci., Arthritis Research UK Professor of Rheumatology and Head of the Academic Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, United Kingdom. “This is consistent with mounting evidence supporting a paradigm shift in how and when we initiate different forms of RA therapy, particularly for those patients with progressive disease accompanied by certain poor prognostic markers.”